RCOR · Renovacor, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2021 | FY 2020 |
|---|---|---|
| Revenue | - | - |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| R&D | $2.42M | - |
| SG&A | $805.0K | - |
| Total Operating Expenses | - | $802.0K |
| D&A | $1.0K | - |
| Operating Income | ($18.63M) | ($802.0K) |
| Interest Expense | - | - |
| Income Tax | - | - |
| Net Income | ($14.10M) | ($780.8K) |
| EPS - Basic | - | - |
| EPS - Diluted | - | - |
Balance Sheet
| Line item | FY 2021 | FY 2020 |
|---|---|---|
| Cash & Equivalents | $78.79M | $687.3K |
| Accounts Receivable | - | - |
| Inventory | - | - |
| Accounts Payable | $1.54M | - |
| Current Assets | $80.55M | $717.5K |
| Total Assets | $81.00M | $86.97M |
| Current Liabilities | $4.03M | - |
| Long-term Debt | - | - |
| Total Liabilities | $27.45M | $859.4K |
| Stockholders' Equity | $53.54M | $23.1K |
| Retained Earnings | ($19.00M) | - |
Cash Flow
| Line item | FY 2021 | FY 2020 |
|---|---|---|
| Operating Cash Flow | ($15.56M) | ($472.9K) |
| Investing Cash Flow | ($20.0K) | ($86.23M) |
| Financing Cash Flow | $88.99M | $87.36M |
| CapEx | $20.0K | - |
| Free Cash Flow | ($15.58M) | - |
Ratios
| Metric | FY 2021 | FY 2020 |
|---|---|---|
| Profitability | ||
| Gross margin | - | - |
| Operating margin | - | - |
| EBITDA margin | - | - |
| Net margin | - | - |
| Free cash flow margin | - | - |
| FCF / Net income | 1.10 | - |
| R&D / Revenue | - | - |
| SG&A / Revenue | - | - |
| Effective tax rate | - | - |
| Return on assets | -17.4% | -0.9% |
| Return on equity | -26.3% | -3387.3% |
| Return on invested capital | - | - |
| Liquidity | ||
| Current ratio | 19.97 | - |
| Quick ratio | 19.97 | - |
| Cash ratio | 19.53 | - |
| Leverage | ||
| Debt / Equity | - | - |
| Debt / Assets | - | - |
| Debt / EBITDA | - | - |
| Interest coverage | - | - |
| Equity multiplier | 1.51 | 3772.89 |
| Liabilities / Assets | 0.34 | 0.01 |
| Efficiency | ||
| Asset turnover | - | - |
| Inventory turnover | - | - |
| Days sales outstanding | - | - |
| Days inventory outstanding | - | - |
| Days payable outstanding | - | - |
| Cash conversion cycle | - | - |
| Valuation | ||
| P / E | - | - |
| P / B | - | - |
| P / S | - | - |
| EV / EBITDA | - | - |
| Growth | ||
| Revenue growth (YoY) | - | - |
| Revenue CAGR (3y) | - | - |
| Revenue CAGR (5y) | - | - |
| Gross profit growth (YoY) | - | - |
| Operating income growth (YoY) | -2222.9% | - |
| Net income growth (YoY) | -1706.0% | - |
| EPS growth (YoY) | - | - |
| EPS CAGR (3y) | - | - |
| EPS CAGR (5y) | - | - |
| FCF growth (YoY) | - | - |
| FCF CAGR (5y) | - | - |
| Book value growth (YoY) | 232195.0% | - |
Stability scores
Piotroski F-score
FY 2021 · 9-point quality
0/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- -Current ratio improved
- -No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Renovacor against the 5 most active filers in the same SIC group.